Articles related to GLP-1s

“Biomarkers have moved in a healthy direction through the intervention, yet clinical responses did not see a statistically significant benefit during the duration of the trial.” — Alzheimer’s Association

Patients taking GLP-1 receptor agonists lose an average of 7 percent of their facial volume for every 22 pounds lost, mostly from fat pads in the midface—yet clinical trials rarely report facial fat loss as an adverse effect, leaving providers unlikely to counsel patients pretreatment about undesirable facial appearance changes.

Across the board, for all outcomes—acute pancreatitis, all-cause mortality, hospitalizations, ICU admissions—we saw significant reductions in patients on GLP-1s compared to chronic pancreatitis patients not on these drugs.” – Mahmoud Y. Madi, MD

As modest reductions in weight can improve fertility, the risk of unintended pregnancy is significant if effective contraception is not used.

In the STEER study, patients using Wegovy® had greater cardiovascular improvements compared to tirzepatide, indicating that the same CV benefit cannot be generalized across other molecules in the GLP-1 or GIP/GLP-1 classes and may come specifically from the semaglutide molecule.

Tirzepatide use was associated with a little more than double the odds—115 percent—of developing PDR compared with those not on the medication, with most cases occurring in patients who already had mild retinal damage from diabetes.